From c4fa000f1246828c67dc9c06790ec887a73fdc04 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Tue, 24 Mar 2026 04:36:59 +0000 Subject: [PATCH] extract: 2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...of US physicians daily within two years.md | 6 +++++ ...t govern continuously learning software.md | 6 +++++ ...ce-uk-dtac-nice-esf-governance-review.json | 24 +++++++++++++++++++ ...ence-uk-dtac-nice-esf-governance-review.md | 14 ++++++++++- 4 files changed, 49 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.extraction-debug/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.json diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index 0f8b4665..8043e913 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -46,6 +46,12 @@ ARISE report reframes OpenEvidence adoption as shadow-IT workaround behavior rat Sutter Health (3.3M patients, ~12,000 physicians) integrated OpenEvidence into Epic EHR workflows in February 2026, marking the first major health-system-wide EHR embedding. This shifts OpenEvidence from standalone app to in-workflow clinical tool, institutionalizing what ARISE identified as physicians bypassing institutional IT governance. +### Additional Evidence (extend) +*Source: [[2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review]] | Added: 2026-03-24* + +iatroX reports OE has 'signalled plans for global expansion as a key 2026 and beyond initiative' with UK, Canada, Australia identified as 'English-first markets with lower regulatory barriers.' However, iatroX notes this perception may be inaccurate for UK: NHS requires DTAC + MHRA Class 1 for formal deployment. OE's characterization of UK as having 'lower regulatory barriers' relative to US may be a strategic misjudgment—UK NHS has MORE formal digital health procurement governance than US (no federal equivalent to DTAC). + + diff --git a/domains/health/healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software.md b/domains/health/healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software.md index d388a38f..921220ab 100644 --- a/domains/health/healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software.md +++ b/domains/health/healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software.md @@ -19,6 +19,12 @@ The AI payment problem compounds the regulatory gap. No payer currently reimburs --- +### Additional Evidence (extend) +*Source: [[2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review]] | Added: 2026-03-24* + +UK NHS governance provides a contrasting model: DTAC (Digital Technology Assessment Criteria) + MHRA Class 1 registration + NICE Evidence Standards Framework creates a multi-layer assessment specifically for digital health tools. NHS England launched a supplier registry in January 2026 with 19 registered ambient voice transcription suppliers, all DTAC-compliant. This demonstrates an alternative regulatory approach to AI clinical tools that is more comprehensive than FDA's device-focused model. + + Relevant Notes: - [[the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification]] -- the FDA has already created flexibility for wellness devices; clinical AI needs a parallel regulatory innovation - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] -- AI payment gaps may accelerate VBC adoption by making fee-for-service untenable for AI-enabled care diff --git a/inbox/queue/.extraction-debug/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.json b/inbox/queue/.extraction-debug/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.json new file mode 100644 index 00000000..e3881dc0 --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.json @@ -0,0 +1,24 @@ +{ + "rejected_claims": [ + { + "filename": "openevidence-us-corpus-creates-uk-clinical-safety-risk-through-guideline-mismatch.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 1, + "rejected": 1, + "fixes_applied": [ + "openevidence-us-corpus-creates-uk-clinical-safety-risk-through-guideline-mismatch.md:set_created:2026-03-24" + ], + "rejections": [ + "openevidence-us-corpus-creates-uk-clinical-safety-risk-through-guideline-mismatch.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-24" +} \ No newline at end of file diff --git a/inbox/queue/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.md b/inbox/queue/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.md index 8019692f..c736ff67 100644 --- a/inbox/queue/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.md +++ b/inbox/queue/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.md @@ -7,9 +7,13 @@ date: 2026-03-20 domain: health secondary_domains: [] format: blog-analysis -status: unprocessed +status: enrichment priority: medium tags: [openevidence, nhs-dtac, nice-esf, uk-healthcare, clinical-ai-safety, belief-5, regulatory-compliance, corpus-bias] +processed_by: vida +processed_date: 2026-03-24 +enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -70,3 +74,11 @@ iatroX Clinical AI Insights is a UK-focused clinical AI review publication that PRIMARY CONNECTION: OE model opacity thread (Sessions 8-11) — extended to UK clinical corpus mismatch WHY ARCHIVED: Provides a previously undocumented clinical risk category for OE in non-US markets: guideline mismatch, not just LLM failure modes EXTRACTION HINT: Extract as "OE UK deployment risk" claim, keeping scope to UK clinical practice (NICE vs. AHA corpus misalignment); link to DTAC absence finding + + +## Key Facts +- NHS England launched ambient scribing supplier registry in January 2026 with 19 registered vendors +- NHS England's April 2025 ambient scribing guidance requires clinical safety case (DCB0160), DPIA, mandatory human verification +- DTAC V2 deadline was April 6, 2026 +- OpenEvidence Visits launched August 2025 as hybrid documentation+CDSS tool +- UK-native DTAC-compliant alternatives include: iatroX, Medwise AI, Praktiki, Pathway